ARHGAP33

Across TCGA pan-cancer cohorts, ARHGAP33 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ARHGAP33 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ARHGAP33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP33 expression acts as an unfavorable survival marker.

LUSC, CESC, and BRCA are the cancer types where ARHGAP33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.011	0.819	<.001	27	view →
CESC	OS	Median	All	0.540	0.802	.020	18	view →
BRCA	DFS	Median	II,III,IV	0.230	0.889	<.001	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.110	0.778	<.001	6	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	6	view →
SKCM	DFS	Median	III,IV	0.063	0.648	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARHGAP33–LUSC (OS)

Open the LUSC breakdown →